Compile Data Set for Download or QSAR
Report error Found 15189 Enz. Inhib. hit(s) with Target = 'Kappa-type opioid receptor'
TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM166783(US9688638, 1 | US9688638, 2 | US9688638, 3)
Affinity DataEC50:  153nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2018
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM166783(US9688638, 1 | US9688638, 2 | US9688638, 3)
Affinity DataEC50:  139nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2018
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM166783(US9688638, 1 | US9688638, 2 | US9688638, 3)
Affinity DataEC50:  122nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2018
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM168144(US9688638, 4 | US9688638, 5 | US9688638, 6 | US108...)
Affinity DataEC50:  9.35nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2018
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM168144(US9688638, 4 | US9688638, 5 | US9688638, 6 | US108...)
Affinity DataEC50:  350nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2018
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM168144(US9688638, 4 | US9688638, 5 | US9688638, 6 | US108...)
Affinity DataEC50:  357nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2018
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM168147(US9688638, 12 | US10081602, Example 12)
Affinity DataEC50:  7nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2018
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM168148(US9688638, 20 | US10081602, Example 20 | US1086518...)
Affinity DataEC50:  6.10nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2018
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM168149(US9688638, 23 | US10081602, Example 23 | US1086518...)
Affinity DataEC50:  395nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2018
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM168150(US9688638, 24 | US10081602, Example 24 | US1086518...)
Affinity DataEC50:  107nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2018
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM168151(US9688638, 25 | US10081602, Example 25)
Affinity DataEC50:  195nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2018
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM50027366(Ketazocine | WIN-34276 | US9688638, Ketazocine | U...)
Affinity DataEC50:  0.550nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2018
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM285816(US10081602, Example 1 | (2S, 6R, 11R)-3-(Cycloprop...)
Affinity DataEC50:  153nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM285847(US10081602, Example 2 | (2S,6R,11R)-3-(Cyclopropyl...)
Affinity DataEC50:  139nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM285848(US10081602, Example 3 | (2S,6R,11R)-3-(Cyclopropyl...)
Affinity DataEC50:  122nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM285849(US10081602, Example 4 | (2S,6R,11R)-3-(Cyclopropyl...)
Affinity DataEC50:  9.35nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM285850(US10081602, Example 5 | (2S,6R,11R)-3-(Cyclopropyl...)
Affinity DataEC50:  350nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM285851(US10081602, Example 6 | (2S,6R,11R)-3-(Cyclopropyl...)
Affinity DataEC50:  357nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM168147(US9688638, 12 | US10081602, Example 12)
Affinity DataEC50:  7nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM168148(US9688638, 20 | US10081602, Example 20 | US1086518...)
Affinity DataEC50:  6.10nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM168149(US9688638, 23 | US10081602, Example 23 | US1086518...)
Affinity DataEC50:  395nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM168150(US9688638, 24 | US10081602, Example 24 | US1086518...)
Affinity DataEC50:  107nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM168151(US9688638, 25 | US10081602, Example 25)
Affinity DataEC50:  195nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM50027366(Ketazocine | WIN-34276 | US9688638, Ketazocine | U...)
Affinity DataEC50:  0.550nMAssay Description:Inhibition of cAMP accumulation by select compounds was measured in forskolin-stimulated CHO-K1 cells stably expressing KOR. CHO-K1 cells stably expr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM303061(US9598447, Ref No. AA)
Affinity DataEC50:  2.00E+4nMAssay Description:κ-Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kappa opioid receptor (kappa) (cloned ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM303064(US9598447, Ref No. FF)
Affinity DataEC50:  2.00E+4nMAssay Description:κ-Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kappa opioid receptor (kappa) (cloned ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM303069(US9598447, Ref No. PP)
Affinity DataEC50:  2.00E+4nMAssay Description:κ-Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kappa opioid receptor (kappa) (cloned ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM303070(US9598447, Ref No. QQ)
Affinity DataEC50:  2.00E+4nMAssay Description:κ-Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kappa opioid receptor (kappa) (cloned ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM303071(US9598447, Ref No. TT)
Affinity DataEC50:  2.00E+4nMAssay Description:κ-Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kappa opioid receptor (kappa) (cloned ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM303072(US9598447, Ref No. VV)
Affinity DataEC50:  2.00E+4nMAssay Description:κ-Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kappa opioid receptor (kappa) (cloned ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM303073(US9598447, Ref No. WW)
Affinity DataEC50:  2.00E+4nMAssay Description:κ-Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kappa opioid receptor (kappa) (cloned ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM309329(US9656962, Compound 6 | (2R,3aS,4R,9bS)-12-(cyclop...)
Affinity DataEC50:  0.860nMAssay Description:Radioligand binding assays (screening and dose-displacement) use 0.1 nM [3H]-nociceptin (Perkin Elmer, Shelton, Conn.; 87.7 Ci/mmole) with 12 μg...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2019
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM309331(US9656962, Compound 7 | (2R,3aS,4R,9bS)-12-(cyclop...)
Affinity DataEC50:  0.800nMAssay Description:Radioligand binding assays (screening and dose-displacement) use 0.1 nM [3H]-nociceptin (Perkin Elmer, Shelton, Conn.; 87.7 Ci/mmole) with 12 μg...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2019
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM309366(US9656962, Compound 12 | (2R,3aS,4R,9bS)-methyl-12...)
Affinity DataEC50:  2.95nMAssay Description:Radioligand binding assays (screening and dose-displacement) use 0.1 nM [3H]-nociceptin (Perkin Elmer, Shelton, Conn.; 87.7 Ci/mmole) with 12 μg...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2019
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM309374(US9656962, Compound 16 | (2R,3aS,4R,9bS)-12-(cyclo...)
Affinity DataEC50:  12.4nMAssay Description:Radioligand binding assays (screening and dose-displacement) use 0.1 nM [3H]-nociceptin (Perkin Elmer, Shelton, Conn.; 87.7 Ci/mmole) with 12 μg...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2019
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM309418(US9656962, Compound 22 | (2R,3aS,4R,9bS)-2-amino-1...)
Affinity DataEC50:  25.7nMAssay Description:Radioligand binding assays (screening and dose-displacement) use 0.1 nM [3H]-nociceptin (Perkin Elmer, Shelton, Conn.; 87.7 Ci/mmole) with 12 μg...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2019
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM309421(US9656962, Compound 30 | (2S,3aS,4R,9bS)-12-(cyclo...)
Affinity DataEC50:  2.49nMAssay Description:Radioligand binding assays (screening and dose-displacement) use 0.1 nM [3H]-nociceptin (Perkin Elmer, Shelton, Conn.; 87.7 Ci/mmole) with 12 μg...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2019
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM309406(US9656962, Compound 31 | (2R,3aS,4R,9bS)-12-(cyclo...)
Affinity DataEC50:  6.95nMAssay Description:Radioligand binding assays (screening and dose-displacement) use 0.1 nM [3H]-nociceptin (Perkin Elmer, Shelton, Conn.; 87.7 Ci/mmole) with 12 μg...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2019
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM309408(US9656962, Compound 33 | (2R,3aS,4R,9bS)-N-benzyl-...)
Affinity DataEC50:  7.03nMAssay Description:Radioligand binding assays (screening and dose-displacement) use 0.1 nM [3H]-nociceptin (Perkin Elmer, Shelton, Conn.; 87.7 Ci/mmole) with 12 μg...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2019
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM309411(US9656962, Compound 34 | (2S,3aS,4R,9bS)-N-benzyl-...)
Affinity DataEC50:  0.0940nMAssay Description:Radioligand binding assays (screening and dose-displacement) use 0.1 nM [3H]-nociceptin (Perkin Elmer, Shelton, Conn.; 87.7 Ci/mmole) with 12 μg...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2019
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM309422(US9656962, Compound 36 | (2S,3aS,4R,9bS)-12-(cyclo...)
Affinity DataEC50:  2.24nMAssay Description:Radioligand binding assays (screening and dose-displacement) use 0.1 nM [3H]-nociceptin (Perkin Elmer, Shelton, Conn.; 87.7 Ci/mmole) with 12 μg...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2019
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM309423(US9656962, Compound 37 | (2R,3aS,4R,9bS)-12-(cyclo...)
Affinity DataEC50:  1.74nMAssay Description:Radioligand binding assays (screening and dose-displacement) use 0.1 nM [3H]-nociceptin (Perkin Elmer, Shelton, Conn.; 87.7 Ci/mmole) with 12 μg...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2019
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM309413(US9656962, Compound 38 | (2S,3aS,4R,9bS)-12-(cyclo...)
Affinity DataEC50:  0.430nMAssay Description:Radioligand binding assays (screening and dose-displacement) use 0.1 nM [3H]-nociceptin (Perkin Elmer, Shelton, Conn.; 87.7 Ci/mmole) with 12 μg...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2019
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM309426(US9656962, Compound 41 | (2R,3aS,4R,9bS)-12-(cyclo...)
Affinity DataEC50:  1.74nMAssay Description:Radioligand binding assays (screening and dose-displacement) use 0.1 nM [3H]-nociceptin (Perkin Elmer, Shelton, Conn.; 87.7 Ci/mmole) with 12 μg...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2019
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM309414(US9656962, Compound 42 | (2S,3aS,4R,9bS)-12-(cyclo...)
Affinity DataEC50:  0.320nMAssay Description:Radioligand binding assays (screening and dose-displacement) use 0.1 nM [3H]-nociceptin (Perkin Elmer, Shelton, Conn.; 87.7 Ci/mmole) with 12 μg...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2019
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM309430(US9656962, Compound 46 | (2R,3aS,4R,9bS)-12-(cyclo...)
Affinity DataEC50:  0.200nMAssay Description:Radioligand binding assays (screening and dose-displacement) use 0.1 nM [3H]-nociceptin (Perkin Elmer, Shelton, Conn.; 87.7 Ci/mmole) with 12 μg...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2019
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM309432(US9656962, Compound 47 | (2S,3aS,4R,9bS)-12-(cyclo...)
Affinity DataEC50:  0.0300nMAssay Description:Radioligand binding assays (screening and dose-displacement) use 0.1 nM [3H]-nociceptin (Perkin Elmer, Shelton, Conn.; 87.7 Ci/mmole) with 12 μg...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2019
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM309415(US9656962, Compound 93 | (2S,3aS,4R,9bS)-12-(cyclo...)
Affinity DataEC50:  1.52nMAssay Description:Radioligand binding assays (screening and dose-displacement) use 0.1 nM [3H]-nociceptin (Perkin Elmer, Shelton, Conn.; 87.7 Ci/mmole) with 12 μg...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2019
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM393487(US9963460, 13)
Affinity DataEC50:  0.00280nMAssay Description:In a [3SS] GTPγS binding test, the opioid receptor agonist activity of test compounds based on a GTP-GDP exchange reaction was evaluated. In the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2020
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM397186(US9988392, Compound 6)
Affinity DataEC50:  0.0850nMAssay Description:κ-Opioid: Receptor Binding Assay Procedures: Membranes from HEK-293, CHO or U-2 OS cells expressing the recombinant human kappa opioid receptor ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/30/2020
Entry Details
US Patent

Displayed 1 to 50 (of 15189 total ) | Next | Last >>
Jump to: